Ajita Narayan
Internal Medicine · Lafayette, INNPI 1467663856
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.8% of the total across 42 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 23 manufacturers, the largest accounting for just 9.6% — the pattern of someone who eats at a lot of different presentations.
Across 42 payments — averaging $22.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- E.r. Squibb & Sons, L.L.C.$92
- Johnson & Johnson$86
- Beigene USA, Inc.$82
- AstraZeneca$74
- Merck$71
- Tempus AI, Inc$57
- plus $494 from 17 others
Across 66 payments — averaging $14,401 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Merck$485K
- AbbVie$410K
- Genentech, Inc.$50K
- Pfizer$5K
- Pharmacyclics LLC, An Abbvie Company$150
What the payments were for
- Food & beverage$94499%
- Education$121%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| E.r. Squibb & Sons, L.L.C. | 2 | $92 |
| Johnson & Johnson | 4 | $86 |
| Beigene USA, Inc. | 1 | $82 |
| AstraZeneca | 2 | $74 |
| Merck | 5 | $71 |
| Tempus AI, Inc | 3 | $57 |
| Lilly USA, LLC | 3 | $57 |
| Genentech USA, Inc. | 3 | $56 |
| Amgen | 2 | $50 |
| Sanofi | 2 | $49 |
| Exelixis Inc. | 1 | $43 |
| AbbVie | 2 | $35 |
| Jazz Pharmaceuticals Inc. | 1 | $31 |
| GSK | 2 | $30 |
| Medtronic | 1 | $24 |
| Novartis | 1 | $23 |
| Pharmacyclics LLC, An Abbvie Company | 1 | $17 |
| Array Biopharma Inc | 1 | $15 |
| Incyte Corporation | 1 | $15 |
| Clovis Oncology, Inc. | 1 | $13 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $12 |
| Pfizer | 1 | $12 |
| Gilead | 1 | $12 |
How this compares
$956 in reported general payments places this provider in the 75th percentile of 1,747 internal medicine providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JakafiRuxolitinib Phosphate | 20 | $357,628 |
| Lenalidomide | 27 | $343,142 |
| VenclextaVenetoclax | 33 | $339,187 |
| CalquenceAcalabrutinib Maleate | 23 | $217,786 |
| RevlimidLenalidomide | 12 | $209,608 |
| BrukinsaZanubrutinib | 16 | $168,109 |
| EliquisApixaban | 101 | $83,852 |
| XareltoRivaroxaban | 30 | $25,944 |
| Anastrozole | 138 | $2,477 |
| Gabapentin | 72 | $1,007 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 40 | $793 |
| Ondansetron OdtOndansetron | 30 | $508 |
| Letrozole | 25 | $508 |
| Morphine Sulfate ErMorphine Sulfate | 12 | $507 |
| Dexamethasone | 26 | $479 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Incyte CorporationJakafi | $15 | $357,62820 claims |
| AbbVieVenclexta | $35 | $339,18733 claims |
| AstraZenecaCalquence | $74 | $217,78623 claims |
| Beigene USA, Inc.Brukinsa | $82 | $168,10916 claims |
| PfizerEliquis | $12 | $83,852101 claims |
| Johnson & JohnsonXarelto | $86 | $25,94430 claims |
| Lilly USA, LLCOlanzapine | $57 | $20712 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,747 internal medicine providers in Indiana.
Other internal medicine in Lafayette
- Robert RussellLafayette$19K
- Abhinav SinghGreenwood$733K
- Girish KunapareddyTerre Haute$329K
- Raj VuppalanchiIndianapolis$279K
- Joseph Arulandula Porte$251K
- Napoleon MamintaIndianapolis$116K
- Jennifer PaisleyLawrenceburg$112K
- Allon FriedmanIndianapolis$111K
- John AyresIndianapolis$107K
- Emily FrankLebanon$100K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.